Hasegawa et al. (2017) showed that stimulation of DRN terminals in the AMY increased 5HT release and decreased cFos in the CeA/LA/BLA (reducing neural activity; Hasegawa et al., 2017). Optogenetic stimulation of this pathway in Orx-Ataxin3 mice decreased cataplexy-like episodes (CLEs). Similar to earlier work in Orx KO mice described above, these authors went on to show that Gq-DREADD excitation of the CeA in Orx-Ataxin3 mice also led to increased cataplexy, while Gi-DREADD inhibition of the CeA led to decreased cataplexy (Hasegawa et al., 2017). The gene discussed is FOS; the disease is Cataplexy.